Malladi Drugs and Pharmaceuticals Limited (90460042)
IPO (In Principle): Malladi Drugs and Pharmaceuticals Limited
π IPO IN-PRINCIPLE APPROVAL β Malladi Drugs and Pharmaceuticals Limited
_Malladi Drugs and Pharmaceuticals Limited manufactures and supplies active pharmaceutical ingredients and intermediates for various therapeutic segments_
Issue Size: βΉ15.06bn
Est. Mcap: βΉ5,020β10,040cr
Face Value: βΉ5
Industry: Pharmaceuticals & Biotechnology
Exchange: BSE And NSE
Promoters: Prashant Malladi, Shreya Sistla, Rohit Malladi
BRLM: Axis Bank Limited, Equirus Capital Private Limited, IIFL Securities Limited, Other LM / BRLM
Eligibility: Regulation 6(2)
Source: Original filing PDF
—
view on exchange portal
β‘ You're reading this after the fact β subscribers got it instantly
ISA
Indian Stock Alerts
BOT
π¨ 90460042 β Quarterly Results
Revenue: βΉ2,35,800 Cr (+12% YoY)
PAT: βΉ19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared βΉ10/share dividend. Jio adds 8M subs.
π bseindia.com/xml-data/...
π§ Audio summary ready
ββ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins β auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades β within minutes
Add 90460042 to your watchlist β all of this, automated.
Sign in with Google14-day Pro trial Β· No credit card Β· Cancel anytime
More on Malladi Drugs and Pharmaceuticals Limited
Important.
The summary above is generated automatically from Malladi Drugs and Pharmaceuticals Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.